Penumbra Inc（PEN）財務資料PENPenumbra Inc

Penumbra, Inc. (PEN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Thrombectomy, accounting for 66.4% of total sales, equivalent to $258.98M. Another important revenue stream is Embolization and Access. Understanding this composition is critical for investors evaluating how PEN navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Penumbra, Inc. maintains a gross margin of 67.78%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 10.37%, while the net margin is 8.81%. These profitability ratios, combined with a Return on Equity (ROE) of 11.37%, provide a clear picture of how effectively PEN converts its operational activities into shareholder value.

In the context of the broader market, PEN competes directly with industry leaders such as BAX and AVTR. With a market capitalization of $12.70B, it holds a significant position in the sector. When comparing efficiency, PEN's gross margin of 67.78% stands against BAX's 35.41% and AVTR's 31.73%. Such benchmarking helps identify whether Penumbra, Inc. is trading at a premium or discount relative to its financial performance.

Penumbra has shown consistent revenue growth, with total revenue reaching $390 million in Q2 2026, a 12.5% increase year-over-year. The gross profit margin has improved to 67.9%, up 1.9% from the previous year, indicating enhanced profitability.